IL312211A - Formulations - Google Patents

Formulations

Info

Publication number
IL312211A
IL312211A IL312211A IL31221124A IL312211A IL 312211 A IL312211 A IL 312211A IL 312211 A IL312211 A IL 312211A IL 31221124 A IL31221124 A IL 31221124A IL 312211 A IL312211 A IL 312211A
Authority
IL
Israel
Prior art keywords
liquid formulation
stable liquid
arginine
formulation according
antibody
Prior art date
Application number
IL312211A
Other languages
English (en)
Hebrew (he)
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of IL312211A publication Critical patent/IL312211A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
IL312211A 2021-10-21 2022-10-20 Formulations IL312211A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115127.9A GB202115127D0 (en) 2021-10-21 2021-10-21 Formulations
PCT/EP2022/079185 WO2023067051A1 (en) 2021-10-21 2022-10-20 Formulations

Publications (1)

Publication Number Publication Date
IL312211A true IL312211A (en) 2024-06-01

Family

ID=78806159

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312211A IL312211A (en) 2021-10-21 2022-10-20 Formulations

Country Status (17)

Country Link
US (1) US20250281403A1 (https=)
EP (1) EP4419077A1 (https=)
JP (1) JP2024539502A (https=)
KR (1) KR20240099316A (https=)
CN (1) CN118175989A (https=)
AR (1) AR127420A1 (https=)
AU (1) AU2022369042A1 (https=)
CA (1) CA3235492A1 (https=)
CL (1) CL2024001232A1 (https=)
CO (1) CO2024006206A2 (https=)
GB (1) GB202115127D0 (https=)
GE (2) GEAP202416521A (https=)
IL (1) IL312211A (https=)
MX (1) MX2024004873A (https=)
PE (1) PE20241192A1 (https=)
TW (1) TW202330029A (https=)
WO (1) WO2023067051A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
CN109563161A (zh) * 2016-02-03 2019-04-02 安口生物公司 用于提高抗体稳定性的缓冲制剂

Also Published As

Publication number Publication date
CA3235492A1 (en) 2023-04-27
US20250281403A1 (en) 2025-09-11
PE20241192A1 (es) 2024-06-03
GEAP202416521A (en) 2024-07-25
CO2024006206A2 (es) 2024-05-30
AR127420A1 (es) 2024-01-24
CL2024001232A1 (es) 2024-09-13
WO2023067051A1 (en) 2023-04-27
KR20240099316A (ko) 2024-06-28
GB202115127D0 (en) 2021-12-08
MX2024004873A (es) 2024-05-06
JP2024539502A (ja) 2024-10-28
GEP20257801B (en) 2025-09-25
EP4419077A1 (en) 2024-08-28
TW202330029A (zh) 2023-08-01
CN118175989A (zh) 2024-06-11
AU2022369042A1 (en) 2024-06-06

Similar Documents

Publication Publication Date Title
EP3681483B1 (en) Process for lyophilized pharmaceutical formulation of a therapeutic protein
TW201625221A (zh) 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
RU2011142184A (ru) Фармацевтический состав, содержащий молекулы антител с улучшенными свойствами
AR109494A1 (es) Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad y altamente concentradas, kits, y métodos
JP6078129B2 (ja) 安定mia/cd−rap製剤
RU2011151286A (ru) Лиофилизированные рецептуры для малых модульных иммунофармацевтических средств
JP2012121894A (ja) Il−1アンタゴニスト製剤
RU2005128280A (ru) Композиции иммуноглобулина и способ их получения
TWI857996B (zh) 含高濃度抗vegf抗體之蛋白質溶液配製物
WO2016155595A1 (zh) 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
EP2582394A1 (fr) Composition d'immunoglobulines humaines stabilisee
WO2022135395A1 (zh) 稳定的抗体制剂及其制备方法和应用
JP2023553538A5 (https=)
IL276911B2 (en) Variants of the carboxylation rate of antibodies
IL312211A (en) Formulations
US10485870B2 (en) Stable pharmaceutical solution formulation of GLP-1R antibody fusion protein
KR20220034053A (ko) 재조합 단백질의 안정적인 제형
IL312207A (en) formulations
JPS6016406B2 (ja) 静脈内に投与可能なガンマ・グロブリンの製造法ならびにそれにより調製したガンマ・グロブリン
JPH0118920B2 (https=)
RU2024113529A (ru) Составы
JP2024539502A5 (https=)
JP2655667B2 (ja) 抗体を含有する安定水性組成物
RU2024113527A (ru) Композиции
CN104740630A (zh) 一种含有抗cd52单抗的药物组合物